FrancophonIA/ELRC3.0 huggingface dataset:
English: Peel back foil to reveal a single oral lyophilisate in the form of a round tablet.
Danish: Blisterfolien åbnes, hvorved en enkelt smeltetablet, der er en rund tablet, kommer til syne.
English: Use is contraindicated in animals suffering from cardiac or hepatic disease, or where there is a history of gastrointestinal ulceration, or bleeding, or where there is hypersensitivity to the product.
Danish: Brugen til hunde med hjerte- eller lever- sygdom, eller hunde med sår eller blødning i mavetarmkanalen er kontraindiceret, eller hvor der er overfølsomhed overfor produktet.
English: Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates for dogs Tepoxalin
Danish: Zubrin 50 mg smeltetabletter til hunde Zubrin 100 mg smeltetabletter til hunde Zubrin 200 mg smeltetabletter til hunde Tepoxalin
English: Tepoxalin is not watersoluble and becomes very sticky upon wetting.
Danish: Tepoxalin er ikke vandopløseligt og bliver meget klistret ved kontakt med fugt.
English: 200 mg / oral lyophilisate
Danish: 200 mg / smeltetablet
English: Ensure hands are dry to prevent the tablet from sticking to fingers.
Danish: Hænderne bør være tørre for at undgå, at tabletten klistrer til fingrene.
English: If gastrointestinal bleeding is suspected, administer gastric protectants.
Danish: Hvis gastrointestinal blødning opstår behandles dette med mavesårsmedicin.
English: 50 mg / oral lyophilisate
Danish: 50 mg / smeltetablet
English: Zubrin oral lyophilisates for dogs
Danish: Zubrin smeltetabletter til hunde
English: A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH
Danish: A. INDEHAVER(E) AF VIRKSOMHEDSGODKENDELSE ANSVARLIG FOR BATCHFRIGIVELSE
English: 6.5 Nature and composition of immediate packaging Zubrin oral lyophilisates are supplied in boxes with foil blisters.
Danish: Zubrin smeltetabletter leveres i æsker indeholdende blisterkort.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/00/028/002-008
Danish: MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE) EU/2/00/028/002-008
English: 100 mg / oral lyophilisate
Danish: 100 mg / smeltetablet
English: • has had gastrointestinal ulceration or bleeding
Danish: • har haft mavesår eller blødning i mave-tarmkanalen
English: Push the bottom of the blister and the tablet will pop out.
Danish: Tabletten trykkes ud ved at trykke under blisteren.
English: 10 oral lyophilisates (EU/2/00/028/006) 30 oral lyophilisates (EU/2/00/028/007) 60 oral lyophilisates (EU/2/00/028/008)
Danish: 10 smeltetabletter (EU/2/00/028/006) 30 smeltetabletter (EU/2/00/028/007) 60 smeltetabletter (EU/2/00/028/008)
English: 4.9 Amounts to be administered and administration route
Danish: 4.9 Dosering og indgivelsesmåde
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE {200 mg oral lyophilisate}
Danish: OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE {200 mg smeltetablet}
English: Do not use in pregnant or lactating dogs or in bitches intended for breeding.
Danish: Bør ikke anvendes til avlstæver, drægtige eller lakterende tæver.
English: 10 oral lyophilisates (EU/2/00/028/004) 30 oral lyophilisates (EU/2/00/028/005)
Danish: 10 smeltetabletter (EU/2/00/028/004) 30 smeltetabletter (EU/2/00/028/005)
English: Ensure hands are dry to prevent the oral lyophilisate from sticking to fingers.
Danish: Hænderne skal være tørre for at undgå, at smeltetabletten klistrer til fingrene.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE {50 mg oral lyophilisate}
Danish: OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE {50 mg smeltetablet}
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs
Danish: VETERINÆRLÆGEMIDLETS NAVN Zubrin 50 mg smeltetabletter til hunde
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE {100 mg oral lyophilisate}
Danish: OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE {100 mg smeltetablet}
English: 10 oral lyophilisates (EU/2/00/028/002) 30 oral lyophilisates (EU/2/00/028/003)
Danish: 10 smeltetabletter (EU/2/00/028/002) 30 smeltetabletter (EU/2/00/028/003)
English: Monitor the hematocrit frequently.
Danish: Hæmatokritten bør monitoreres jævnligt.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 200 mg oral lyophilisates for dogs
Danish: VETERINÆRLÆGEMIDLETS NAVN Zubrin 200 mg smeltetabletter til hunde
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 100 mg oral lyophilisates for dogs
Danish: VETERINÆRLÆGEMIDLETS NAVN Zubrin 100 mg smeltetabletter til hunde
English: No accumulation of tepoxalin or its acid metabolite was detected after multiple dosing over a broad dose range.
Danish: Selv efter adskillige doseringer med forskellige doser sås ingen akkumulation af hverken tepoxalin eller syremetabolitten.
English: Do not use in pregnant or lactating bitches.
Danish: Bør ikke anvendes til drægtige eller lakterende tæver.
English: EU/2/00/028/008 (6 blisters)
Danish: EU/2/00/028/008 (6 blisterkort)
English: MARKETING AUTHORISATION NUMBER(S) EU/2/00/028/006 (1 blister)
Danish: MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE) EU/2/00/028/006 (1 blisterkort)
English: 1 box containing 1 or 3 blisters.
Danish: 50 mg, 100 mg: 1 æske indeholdende 1 eller 3 blisterkort.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/00/028/004 (1 blister)
Danish: MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE) EU/2/00/028/004 (1 blisterkort)
English: MARKETING AUTHORISATION NUMBER(S) EU/2/00/028/002 (1 blister)
Danish: MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE) EU/2/00/028/002 (1 blisterkort)
English: EU/2/00/028/005 (3 blisters)
Danish: EU/2/00/028/005 (3 blisterkort)
English: EU/2/00/028/007 (3 blisters)
Danish: EU/2/00/028/007 (3 blisterkort)
English: EU/2/00/028/003 (3 blisters)
Danish: EU/2/00/028/003 (3 blisterkort)
English: List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation holders in the member states
Danish: FORTEGNELSE OVER LÆGEMIDLERNES NAVNE, LÆGEMIDDELFORM, STYRKER, INDGIVELSESVEJ, INDEHAVERE AF MARKEDSFØRINGSTILLADELSER I MEDLEMSSTATERNE
English: Otsuka Pharmaceutical Europe Ltd.Huton House Highbridge Busines Park, Oxford Road Uxbridge, Middlesex,
Danish: Otsuka Pharmaceutical Europe Ltd. Hunton House Highbridge Estate Oxford Road Uxbridge GB-UB8 1LX MIDDLESEX United Kingdom United Kingdom
English: This effect was maintained for up to four years.
Danish: Virkningen blev fastholdt i op til fire år.
English: These were measured before and after 26 weeks of treatment.
Danish: Dette blev målt før og efter 26 ugers behandling.
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 16 December 2015.
Danish: Efter at virksomheden havde fremlagt de udbedte yderligere oplysninger, blev de "særlige omstændigheder" ophævet den 16. december 2015.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Aldurazyme on 10 June 2003.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Aldurazyme den 10. juni 2003.
English: Half of the children treated had a normal size liver at the end of the study.
Danish: Halvdelen af de behandlede børn havde en lever af normal størrelse ved undersøgelsens slutning.
English: This is a summary of the European public assessment report (EPAR) for Aldurazyme.
Danish: Dette er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Aldurazyme.
English: The full EPAR for Aldurazyme can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Aldurazyme findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: After this, the study continued for up to four years and all of the patients were treated with Aldurazyme.
Danish: Efter dette blev undersøgelsen videreført i fire år, og alle patienter blev behandlet med Aldurazyme.
English: The effect of these on the safety and effectiveness of the medicine is not fully known.
Danish: Det vides endnu ikke helt, hvilken indvirkning disse har på lægemidlets sikkerhed og virkning.
English: Other information about Aldurazyme
Danish: Andre oplysninger om Aldurazyme
English: Some of these are severe, but the number of side effects tends to decrease with time.
Danish: Nogle af disse var svære i intensitet, men antallet af bivirkninger aftog med tiden.
English: Aldurazyme has also been studied in 20 children below the age of five years who received Aldurazyme for a year.
Danish: Aldurazyme er også blevet undersøgt hos 20 børn under fem år, som havde fået Aldurazyme i et år.
English: This means that substances called glycosaminoglycans (GAGs) are not broken down, so they build up in most of the organs in the body and damage them.
Danish: Dette medfører, at visse stoffer kaldet glykosaminoglycaner ikke nedbrydes og således hober sig op i de fleste af kroppens organer og beskadiger dem.
English: In children under five years of age, Aldurazyme reduced the levels of GAGs in the urine by about 60%.
Danish: Hos børn under fem år reducerede Aldurazyme GAG-niveauet i urinen med ca. 60 %.
English: The study was looking mainly at the safety of the medicine, but it also measured its ability to reduce the levels of GAGs in the urine and the size of the liver.
Danish: Undersøgelsen så navnlig på lægemidlets sikkerhed, men målte også dets evne til at reducere GAGniveauet i urinen og leverens størrelse.
English: Almost all patients who receive Aldurazyme develop antibodies (proteins that are produced in response to Aldurazyme).
Danish: Næsten alle patienter, som får Aldurazyme, danner antistoffer (proteiner, der dannes som reaktion på Aldurazyme).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aldurazyme.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Aldurazyme.
English: It is produced by a method known as ‘recombinant DNA technology': the enzyme is made by cells into which a gene (DNA) has been introduced that makes them able to produce laronidase.
Danish: Det fremstilles ved hjælp af en metode kaldet "rekombinant dna-teknologi": Enzymet fremstilles af celler, der har fået indsat et gen (DNA), som gør dem i stand til at producere laronidase.
English: For more information about treatment with Aldurazyme, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Aldurazyme, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: Aldurazyme was originally authorised under ‘exceptional circumstances', because, as the disease is rare, limited information was available at the time of approval.
Danish: Aldurazyme blev oprindeligt godkendt under "særlige omstændigheder", da der på godkendelsestidspunktet kun forelå sparsomme oplysninger som følge af sygdommens sjældenhed.
English: Aldurazyme should be given in a hospital or clinic where resuscitation equipment is available, and patients may need to receive some medicines before the infusion to prevent an allergic reaction.
Danish: Indgivelsen af Aldurazyme skal ske på et hospital eller en klinik, hvor der er genoplivningsudstyr tilgængeligt, og det kan være nødvendigt at give patienterne medicin inden infusionen for at forebygge en allergisk reaktion.
English: MPS I is a rare, inherited disease, in which the level of α L iduronidase enzyme activity is much lower than normal.
Danish: MPS I er en sjælden arvelig sygdom, hvor niveauet for α-L-iduronidase-enzymaktivitet er meget lavere end normalt.
English: It is intended for long-term use.
Danish: Lægemidlet er beregnet til langtidsbehandling.
English: Aldurazyme is given once a week as an infusion into a vein.
Danish: Aldurazyme indgives som en infusion i en vene én gang om ugen.
English: The active substance in Aldurazyme, laronidase, is a copy of the human enzyme α L iduronidase.
Danish: Det aktive stof i Aldurazyme, laronidase, er en kopi af det humane enzym α-L-iduronidase.
English: Aldurazyme must not be used in people who are severely allergic to laronidase or any of the other ingredients.
Danish: Aldurazyme må ikke anvendes til personer, som er overfølsomme over for laronidase eller et af de øvrige indholdsstoffer.
English: What is the risk associated with Aldurazyme?
Danish: Hvilken risiko er der forbundet med Aldurazyme?
English: Aldurazyme treatment should be supervised by a doctor who has experience in the management of patients with MPS I or other inherited metabolic diseases.
Danish: Behandlingen med Aldurazyme skal overvåges af en læge med erfaring i behandling af patienter med MPS I eller andre arvelige stofskiftesygdomme.
English: Aldurazyme is used in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; α L iduronidase deficiency) to treat the non-neurological symptoms of the disease (symptoms that are not connected with the brain or nerves).
Danish: Aldurazyme er indiceret til patienter med den bekræftede diagnose Mucopolysaccharidosis I (MPS I; αL-iduronidase-mangel) til behandling af sygdommens ikke-neurologiske symptomer (symptomer, der ikke er forbundet med hjernen eller nerverne).
English: Most of the side effects seen with Aldurazyme are reactions caused by the infusion procedure rather than the medicine itself.
Danish: De fleste af bivirkningerne ved Aldurazyme var snarere infusionsrelaterede reaktioner end reaktioner forårsaget af selve lægemidlet.
English: The CHMP decided that Aldurazyme gives effective control of the symptoms of MPS I. The Committee decided that Aldurazyme's benefits are greater than its risks and recommended that Aldurazyme be given marketing authorisation.
Danish: CHMP besluttede, at Aldurazyme er virksomt til at kontrollere symptomerne på MPS I. Udvalget besluttede, at fordelene ved Aldurazyme var større end risiciene, og anbefalede derfor udstedelse af en markedsføringstilladelse for Aldurazyme.
English: For the full list of all side effects reported with Aldurazyme, see the package leaflet.
Danish: Den fuldstændige liste over alle de indberettede bivirkninger ved Aldurazyme fremgår af indlægssedlen.
English: Laronidase is used as ‘enzyme replacement therapy', which means that it replaces the enzyme that is missing in patients with MPS I. This controls the symptoms of MPS I, improving the patient's quality of life.
Danish: Laronidase anvendes som erstatningsterapi, hvilket betyder, at det erstatter det enzym, der mangler hos patienter med MPS I. Dette holder symptomerne på MPS I under kontrol, og patientens livskvalitet forbedres.
English: The non-neurological symptoms of MPS I can be an enlarged liver, stiff joints that make moving more difficult, reduced lung volume, heart disease and eye disease.
Danish: De ikke-neurologiske symptomer på MPS I er f.eks. en forstørret lever, stive led, som gør det svært at bevæge sig, nedsat lungefunktion, hjertesygdom og øjensygdom.
English: Aldurazyme has been compared with placebo (a dummy treatment) in 45 patients aged six years and over with a confirmed diagnosis of MPS I. The main measure of effectiveness was the forced vital capacity (FVC, a measure of how well the lungs are working) and the distance the patients could walk over six minutes.
Danish: Aldurazyme er blevet sammenlignet med placebo (en virkningsløs behandling) hos 45 patienter i alderen seks år og derover med den bekræftede diagnose MPS I. Den vigtigste målestok for virkningen var den forcerede vitalkapacitet (målestok for lungefunktionen) og den afstand, patienterne kunne gå på seks minutter.
English: Aldurazyme is a solution for infusion (drip) into a vein that contains the active substance laronidase.
Danish: Aldurazyme er en opløsning til infusion (dråbetilførsel i en vene), der indeholder det aktive stof laronidase.
English: The most common side effects in patients over the age of five years (seen in more than 1 patient in 10) are headache, nausea (feeling sick), abdominal pain (stomach ache), rash, arthropathy (damage to the joints), arthralgia (joint pain), back pain, pain in the extremities (hands and feet), flushing, pyrexia (fever) and reactions at the site of the infusion.
Danish: De hyppigste bivirkninger ved Aldurazyme hos patienter over fem år (som ses hos flere end 1 ud af 10 patienter) er hovedpine, kvalme, mavesmerter, udslæt, artropati (ledskader), artralgi (ledsmerter), rygsmerter, smerter i ekstremiteterne (hænder og fødder), rødme, pyreksi (feber) og reaktioner på infusionsstedet.
English: Why has Aldurazyme been approved?
Danish: Hvorfor blev Aldurazyme godkendt?
English: The study showed that Aldurazyme had improved both the FVC and the walking ability of patients at 26 weeks.
Danish: Undersøgelsen viste, at Aldurazyme efter 26 uger havde forbedret både patienternes forcerede vitalkapacitet og den afstand, de kunne gå.
English: What is Aldurazyme?
Danish: Hvad er Aldurazyme?
English: What benefit has Aldurazyme shown during the studies?
Danish: Hvilken fordel viser undersøgelserne, at der er ved Aldurazyme?
English: In patients under five years of age, the most common side effects (seen in more than 1 patient in 10) are increased blood pressure, decreased oxygen saturation (a measure of how well the lungs are working), tachycardia (rapid heart rate), pyrexia and chills.
Danish: Hos patienter under fem år er de almindeligt forekommende bivirkninger (som optræder hos flere end 1 ud af 10 patienter) forhøjet blodtryk, faldende iltsaturation (en målestok for lungefunktionen), hjertebanken, feber og kulderystelser.
English: How has Aldurazyme been studied?
Danish: Hvordan blev Aldurazyme undersøgt?
English: What is Aldurazyme used for?
Danish: Hvad anvendes Aldurazyme til?
English: How is Aldurazyme used?
Danish: Hvordan anvendes Aldurazyme?
English: How does Aldurazyme work?
Danish: Hvordan virker Aldurazyme?
English: MA (EU) number (Invented) name
Danish: MF (EU)-nummer Særnavn Styrke Lægemiddelform Administration Emballage
English: This summary was last updated in 12-2013.
Danish: Dette sammendrag blev sidst ajourført i 12-2013.
English: Skin reactions are seen in more than 80% of patients.
Danish: Hudreaktioner ses hos over 80 % af patienterne.
English: The following infusions are 250 mg/m2 given over one hour.
Danish: De efterfølgende infusioner er 250 mg/m2 indgivet i løbet af en time.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Erbitux on 29 June 2004.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Erbitux den 29. juni 2004.
English: Erbitux is given once a week.
Danish: Erbitux indgives én gang om ugen.
English: The full EPAR for Erbitux can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Danish: Den fuldstændige EPAR for Erbitux findes på agenturets websted: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: ‘Metastatic' means that the cancer has spread to other parts of the body.
Danish: ”Metastatisk” betyder, at kræften har spredt sig til andre dele af kroppen.
English: Erbitux is given in the following ways:
Danish: Erbitux gives på følgende måder:
English: Patients must also be closely observed for any signs of allergic reaction for at least one hour after the end of the infusion.
Danish: Patienten skal desuden overvåges nøje for tegn på allergiske reaktioner i mindst en time efter, at infusionen er indgivet.
English: This is a summary of the European public assessment report (EPAR) for Erbitux.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Erbitux.
English: All of the studies looked at how long the patients lived without their cancer getting worse or how long they survived.
Danish: I alle undersøgelserne så man på, hvor længe patienterne levede, uden at deres kræftsygdom blev værre, eller hvor lang tid patienterne overlevede.
English: Between 79 and 89% of colorectal cancers and more than 90% of squamous cell cancers of the head and neck have EGFR on their cell surfaces.
Danish: Mellem 79 og 89 % af colorektalkræfttyper og over 90 % af pladecellekræfttyper i hoved-hals-regionen har EGFR på celleoverfladen.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Erbitux.
Danish: Det forklarer, hvordan Udvalget for Humanmedicinske Lægemidler (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om, hvordan Erbitux skal anvendes.
English: The first infusion is given at a dose of 400 mg per square metre body surface area (calculated using the patient's height and weight) over two hours.
Danish: Den første infusion indgives ved en dosis på 400 mg pr. kvadratmeter legemsoverflade (beregnes ved hjælp af patientens højde og vægt) og varer 2 timer.
English: The CHMP decided that Erbitux's benefits are greater than its risks and recommended that it be given marketing authorisation.
Danish: CHMP besluttede, at fordelene ved Erbitux opvejer risiciene, og anbefalede udstedelse af markedsføringstilladelse.
English: EPAR summary for the public cetuximab
Danish: EPAR - sammendrag for offentligheden cetuximab
English: Other information about Erbitux
Danish: Andre oplysninger om Erbitux
English: Erbitux can be associated with severe reactions during the infusion, so the patients must be monitored carefully while the medicine is being given.
Danish: Erbitux kan være forbundet med alvorlige reaktioner under infusionen, så patienterne skal overvåges nøje, mens lægemidlet gives.
English: For more information about treatment with Erbitux, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Erbitux, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) in the body.
Danish: Et monoklonalt antistof er et antistof (en proteintype), som er blevet udviklet til at genkende og binde sig til en specifik struktur (kaldet et antigen), som findes i kroppen.
English: Before receiving Erbitux, the patient must be given an antihistamine and a corticosteroid to prevent an allergic reaction.
Danish: Inden indgivelsen af Erbitux skal patienten have et antihistamin og et kortikosteroid for at forebygge en allergisk reaktion.
English: Erbitux should only be given under the supervision of a doctor who has experience in the use of anticancer medicines in a setting where facilities for resuscitation are available.
Danish: Erbitux må kun gives under overvågning af en læge med erfaring i brug af lægemidler mod kræft på faciliteter, hvor der er genoplivningsudstyr til rådighed.
English: • together with anticancer treatments containing irinotecan;
Danish: • sammen med kræftbehandlinger, der indeholder irinotecan
English: The active substance in Erbitux, cetuximab, is a monoclonal antibody.
Danish: Det aktive stof i Erbitux, cetuximab, er et monoklonalt antistof.
English: These types of cancer affect the cells of the lining of the mouth or the throat, or of organs such as the larynx (voice box).
Danish: Disse kræfttyper angriber cellerne i slimhinden i munden eller halsen, eller i organer såsom larynx (strubehovedet).